Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.33 |
| ▸ | SCD | O00767 | 2/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335443 | 0.94 | CNR2 (0.47) | CNR2CHRNA4MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL3337598 | 0.89 | CNR2 (0.48) | CNR2CHRNA4MBTD1L3MBTL3SCD5 | |
| SCHEMBL3333676 | 0.88 | CHRNA4 (0.48) | CNR2CHRNA4MBTD1L3MBTL3L3MBTL1 | |
| SCHEMBL3336729 | 0.87 | CHRNA4 (0.49) | CNR2CHRNA4L3MBTL1SCD5GRM2 | |
| SCHEMBL3336090 | 0.82 | CNR2 (0.49) | CNR2CHRNA4SCD5GRM2SCD | |
| SCHEMBL3337853 | 0.82 | CHRNA4 (0.49) | CNR2CHRNA4MBTD1L3MBTL3SCD5 | |
| SCHEMBL3337609 | 0.79 | CHRNA4 (0.45) | CHRNA4 | |
| SCHEMBL3336122 | 0.77 | CHRNA4 (0.53) | CNR2CHRNA4L3MBTL3L3MBTL1SCD5 | |
| SCHEMBL3337016 | 0.77 | CHRNA4 (0.44) | CHRNA4MBTD1L3MBTL3 | |
| SCHEMBL3334246 | 0.76 | CHRNA4 (0.62) | CNR2CHRNA4MBTD1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | claimed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144700-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | CHRNA10, CHRNA2, CHRNE | CNR2 46/4885CHRNA4 8/4885MBTD1 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.